In addition to providing excellent care, Memorial Sloan-Kettering Cancer Center is constantly working to develop new and improved treatments for people with lymphoma who are not helped by standard treatments. This research is conducted through our clinical trials program.
Our physicians lead a large number of clinical trials that test new drugs and drug combinations, look for genetic factors that are linked to lymphoma, and explore other strategies for improving treatment for both Hodgkin and non-Hodgkin lymphoma. Our clinical trials are based on our growing understanding of how lymphoma is distinctive from other cancers. This research is increasingly “translational,” bringing discoveries made in the research lab directly to the patient.
This activity means that choosing Memorial Sloan-Kettering for your care may give you access to new treatment options before they are widely available elsewhere. Our clinical research team is highly experienced in selecting patients who are mostly likely to benefit from a particular investigational therapy and can guide you through the process of selecting the most appropriate clinical trial.
Our research efforts fall into the following general categories:
New chemotherapy approaches
Our physicians are investigating the effectiveness of various combinations of chemotherapeutic agents and other drugs for non-Hodgkin lymphoma.
Pathway-directed (biologic) therapies
Our investigators are testing drugs designed to interrupt or inhibit the molecular processes tumor cells require to grow and spread.
Immune strategies
Memorial Sloan-Kettering has an active immunotherapy program testing investigational drugs that encourage the body's immune system to identify and react against cancer cells.
Tumor-directed therapies (radiolabeled antibodies)
Memorial Sloan-Kettering researchers are investigating the effectiveness of antibodies — proteins that specifically target cancer cells and carry radioactive molecules. These drugs can potentially kill cancer cells with radiation while minimizing exposure to the rest of the body.
Here you can find a continually updated listing of Memorial Sloan-Kettering's current clinical trials for patients with lymphomas. To learn more about a study, choose from the list below.
Marginal Zone Lymphoma
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Xenogeneic CD20 DNA Vaccination in Patients with B-cell Lymphoma
Palomba, M. Lia, MD
[Protocol 07-100]
A Phase II Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Horwitz, Steven, MD
[Protocol 12-035]
A Phase I Study of IPI-145 in Patients with Advanced Hematologic Cancers
Horwitz, Steven, MD
[Protocol 12-088]
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Horwitz, Steven, MD
[Protocol 12-170]
A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Moskowitz, Craig, MD
[Protocol 12-282]
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]
Follicular Lymphoma
Untreated (Newly Diagnosed)
A Phase III Study of Rituximab/Lenalidomide or Rituximab/Chemotherapy Followed by Rituximab Maintenance Therapy in Patients with Previously Untreated Follicular Lymphoma
Palomba, M. Lia, MD
[Protocol 12-081]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Xenogeneic CD20 DNA Vaccination in Patients with B-cell Lymphoma
Palomba, M. Lia, MD
[Protocol 07-100]
A Phase II Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Horwitz, Steven, MD
[Protocol 12-035]
A Phase I Study of IPI-145 in Patients with Advanced Hematologic Cancers
Horwitz, Steven, MD
[Protocol 12-088]
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Horwitz, Steven, MD
[Protocol 12-170]
A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Moskowitz, Craig, MD
[Protocol 12-282]
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]
Small Lymphocytic Lymphoma (SLL)
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Xenogeneic CD20 DNA Vaccination in Patients with B-cell Lymphoma
Palomba, M. Lia, MD
[Protocol 07-100]
A Phase II Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Horwitz, Steven, MD
[Protocol 12-035]
A Phase I Study of IPI-145 in Patients with Advanced Hematologic Cancers
Horwitz, Steven, MD
[Protocol 12-088]
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Horwitz, Steven, MD
[Protocol 12-170]
A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Moskowitz, Craig, MD
[Protocol 12-282]
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]
Diffuse Large B-Cell Lymphoma
Untreated (Newly Diagnosed)
A Phase III Study of Ibritumomab Tiuxetan versus Observation in Older Patients with Diffuse Large B-Cell Lymphoma in Remission following R-CHOP
Hamlin, Paul, MD
[Protocol 12-061]
Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma (NCI #9177; AMC #086)
Noy, Ariela, MD
[Protocol: 13-022]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Xenogeneic CD20 DNA Vaccination in Patients with B-cell Lymphoma
Palomba, M. Lia, MD
[Protocol 07-100]
A Phase III Study of Ofatumumab versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Matasar, Matthew, MD
[Protocol 11-079]
A Phase III Study of Inotuzumab Ozogamicin with Rituximab versus Standard Therapy for Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 12-005]
A Phase II Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Horwitz, Steven, MD
[Protocol 12-035]
A Phase I Study of IPI-145 in Patients with Advanced Hematologic Cancers
Horwitz, Steven, MD
[Protocol 12-088]
A Phase I Study of AEB071 in Patients with CD79-Mutant Diffuse Large B-Cell Lymphoma
Gerecitano, John, MD, PhD
[Protocol 12-157]
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Horwitz, Steven, MD
[Protocol 12-170]
A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Moskowitz, Craig, MD
[Protocol 12-282]
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]
Hodgkin Lymphoma
Untreated (Newly Diagnosed)
A Phase II Study of Brentuximab (SGN-35) Given Before and After Adriamycin, Vinblastine, and Dacarbazine Therapy in Older Adults with Untreated Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 11-201]
Prior Treatment (Relapsed/Refractory)
Brentuximab (SGN-35) in Transplant-Eligible Patients with Relapsed or Refractory Hodgkin Lymphoma
Moskowitz, Alison, MD
[Protocol 11-142]
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]
Mantle Cell Lymphoma
Untreated (Newly Diagnosed)
A Phase I/II Study of Sequential Chemoradiation Followed by Autologous Stem Cell Transplant in Patients with Untreated Advanced Mantle Cell Lymphoma
Zelenetz, Andrew, MD, PhD
[Protocol 11-095]
Ofatumumab with or without Bendamustine for Patients with Mantle Cell Lymphoma Who Cannot Have an Autologous Stem Cell Transplant
Hamlin, Paul, MD
[Protocol 11-050]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Xenogeneic CD20 DNA Vaccination in Patients with B-cell Lymphoma
Palomba, M. Lia, MD
[Protocol 07-100]
A Phase I Study of IPI-145 in Patients with Advanced Hematologic Cancers
Horwitz, Steven, MD
[Protocol 12-088]
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Horwitz, Steven, MD
[Protocol 12-170]
A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Moskowitz, Craig, MD
[Protocol 12-282]
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]
Burkitt's Lymphoma
Untreated (Newly Diagnosed
Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma (NCI #9177; AMC #086)
Noy, Ariela, MD
[Protocol: 13-022]
Prior Treatment (Relapsed/Refractory)
High-Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B-Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients
Noy, Ariela, MD
[Protocol 10-181]
Peripheral T Cell Lymphoma
Prior Treatment (Relapsed/Refractory)
PDX-017: A Phase III Study of Pralatrexate Versus Observation in Patients with Peripheral T-Cell Lymphoma Following Initial Chemotherapy
Horwitz, Steven, MD
[Protocol 10-212]
A Phase II Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Horwitz, Steven, MD
[Protocol 12-035]
A Phase I Study of IPI-145 in Patients with Advanced Hematologic Cancers
Horwitz, Steven, MD
[Protocol 12-088]
A Phase II Study of MLN8237 in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Horwitz, Steven, MD
[Protocol 12-096]
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]
HIV+ Lymphoma
Untreated (Newly Diagnosed)
A Phase I/II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
Noy, Ariela, MD
[Protocol 11-013]
Prior Treatment (Relapsed/Refractory)
High-Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B-Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients
Noy, Ariela, MD
[Protocol 10-181]
A Study of Bortezomib plus (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Noy, Ariela, MD
[Protocol 09-063]
Waldenstrom's
Prior Treatment (Relapsed/Refractory)
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Waldenstrom's Macroglobulinemia
Palomba, M. Lia, MD
[Protocol: 12-211]
Adult T Cell Leukemia Lymphoma
Untreated (Newly Diagnosed)
A Phase I/II Study of EPOCH Chemotherapy, Bortezomib, and Raltegravir for the Treatment of HTLV-1-Associated T-Cell Leukemia/Lymphoma
Noy, Ariela, MD
[Protocol 12-146]
Prior Treatment (Relapsed/Refractory)
A Phase I/II Study of EPOCH Chemotherapy, Bortezomib, and Raltegravir for the Treatment of HTLV-1-Associated T-Cell Leukemia/Lymphoma
Noy, Ariela, MD
[Protocol 12-146]
A Phase II Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Horwitz, Steven, MD
[Protocol 12-035]
A Phase II Study of MLN8237 in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Horwitz, Steven, MD
[Protocol 12-096]
